Heron Therapeutics
HRTX
88 hedge funds and large institutions have $1.13B invested in Heron Therapeutics in 2015 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 30 increasing their positions, 20 reducing their positions, and 13 closing their positions.
1,236% more call options, than puts
Call options by funds: $86.4M | Put options by funds: $6.47M
193% more capital invested
Capital invested by funds: $385M → $1.13B (+$741M)
146% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 13
50% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 20
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
28% more funds holding
Funds holding: 69 → 88 (+19)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$34.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$33.2M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$25.5M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$25.4M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
-$9.7M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$8.22M |
| 3 |
BC
Broadfin Capital
New York
|
-$7.74M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.68M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.93M |
HRTX Hedge Fund Activity: Q2 2015 in Review
88 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2015, worth a combined $1.13B — up 193% from $385M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new HRTX positions and 13 closed out — a net gain of 19 holders — while 30 added to existing stakes and 20 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $34.1M. The largest seller was Allianz Asset Management, cutting an estimated $9.7M.
- 88 institutional investors held Heron Therapeutics (HRTX) as of Q2 2015, up from 69 in Q1 2015.
- Funds reported $1.13B of Heron Therapeutics stock for Q2 2015, up 193% quarter-over-quarter.
- 32 funds opened new Heron Therapeutics positions in Q2 2015 and 13 closed out, a net change of +19 holders.
- The largest Heron Therapeutics buyer in Q2 2015 was PFM Health Sciences, an estimated $34.1M added.
- The largest Heron Therapeutics seller in Q2 2015 was Allianz Asset Management, an estimated $9.7M sold.
Based on aggregated 13F filings for Q2 2015.